CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible.
|Titolo:||Third-line salvage chemotherapy in Hodgkin's disease.|
|Data di pubblicazione:||1985|
|Appare nelle tipologie:||1.1 Articolo in rivista|